Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03526705
Recruitment Status : Not yet recruiting
First Posted : May 16, 2018
Last Update Posted : July 23, 2019
Sponsor:
Information provided by (Responsible Party):
Dina Saadi, Cairo University

Brief Summary:

Psoriasis is an immune-mediated skin disease that affects 1-2 % of the population. Several cytokines have been found to be involved in the complex pathogenesis of this disease. Il- 36 is one of the cytokines sharing in psoriasis pathogenesis, as its levels are elevated in psoriatic plaques. Cathepsin G is known to activate Il- 36 and promote inflammation in psoriasis.NB-UVB is one of the important treatment modalities for psoriasis.

The aim of this study is to detect the effect of NB-UVB on the lesional levels of IL-36 in psoriasis.


Condition or disease Intervention/treatment Phase
Psoriasis Device: NB-UVB Not Applicable

Detailed Description:
25 psoriasis patients will receive 26 sessions of phototherapy (NB-UVB). Patients will receive 3 sessions per week. Tissue levels of IL-36 and Cathepsin G will be assessed in skin lesions before starting treatment and after completing the 26 sessions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis Lesional Skin
Estimated Study Start Date : July 15, 2019
Estimated Primary Completion Date : January 15, 2020
Estimated Study Completion Date : January 15, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: nb-uvb
psoriasis patients will receive 26 sessions of nb-uvb phototherapy
Device: NB-UVB
Phototherapy




Primary Outcome Measures :
  1. changes in Il-36 levels in 25 psoriasis patients after 26 sessions of NB-UVB [ Time Frame: 6 months ]
    primary


Secondary Outcome Measures :
  1. changes in cathepsin G levels in 25 psoriasis patients after 26 sessions of NB-UVB psoriasis [ Time Frame: 6 months ]
    secondary



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with psoriasis vulgaris of both sexes
  • Age between 18 and 60 years old.

Exclusion Criteria:

  • Pregnant females
  • Patients receiving systemic treatment or topical treatment for psoriasis within the past two months.
  • Patients having other dermatological diseases.

Layout table for additonal information
Responsible Party: Dina Saadi, Lecturer, Cairo University
ClinicalTrials.gov Identifier: NCT03526705     History of Changes
Other Study ID Numbers: Kapu1
First Posted: May 16, 2018    Key Record Dates
Last Update Posted: July 23, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases